Analysts Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $1,099.55

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has been given a consensus rating of “Moderate Buy” by the twenty-two research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $1,107.29.

REGN has been the topic of a number of research reports. Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 4th. Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Royal Bank of Canada decreased their target price on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st.

Institutional Trading of Regeneron Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. International Assets Investment Management LLC grew its position in shares of Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after acquiring an additional 879,916 shares during the period. Swedbank AB purchased a new position in Regeneron Pharmaceuticals during the first quarter valued at $129,257,000. Worldquant Millennium Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 3rd quarter valued at $127,489,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in Regeneron Pharmaceuticals by 23.8% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 500,274 shares of the biopharmaceutical company’s stock worth $525,804,000 after purchasing an additional 96,266 shares in the last quarter. Finally, TD Asset Management Inc increased its holdings in shares of Regeneron Pharmaceuticals by 30.4% in the second quarter. TD Asset Management Inc now owns 351,545 shares of the biopharmaceutical company’s stock worth $369,484,000 after purchasing an additional 82,034 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $754.87 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm’s fifty day simple moving average is $913.54 and its 200 day simple moving average is $1,020.69. The stock has a market cap of $82.95 billion, a P/E ratio of 18.68, a price-to-earnings-growth ratio of 2.89 and a beta of 0.15. Regeneron Pharmaceuticals has a twelve month low of $735.95 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.